Jazz Pharmaceuticals
JAZZ
455 hedge funds and large institutions have $7.39B invested in Jazz Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 140 increasing their positions, 175 reducing their positions, and 100 closing their positions.
1.46% less ownership
Funds ownership: 94.41% → 92.94% (-1.5%)
10% less funds holding
Funds holding: 505 → 455 (-50)
20% less repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 175
27% less capital invested
Capital invested by funds: $10.1B → $7.39B (-$2.76B)
30% less call options, than puts
Call options by funds: $66.5M | Put options by funds: $95.4M
46% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 100
75% less funds holding in top 10
Funds holding in top 10: 8 → 2 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$163M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$113M |
| 3 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
+$101M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$86.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$138M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$72.7M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
-$72.5M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$52.8M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$52.2M |
JAZZ Hedge Fund Activity: Q3 2021 in Review
455 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2021, worth a combined $7.39B — down 27% from $10.1B a quarter earlier.
Sellers outnumbered buyers: 100 funds closed out of JAZZ and 54 opened new positions — a net loss of 46 holders — while 175 trimmed existing stakes and 140 added.
The largest buyer was Canada Pension Plan Investment Board, adding an estimated $163M. The largest seller was Citadel Advisors, cutting an estimated $138M.
- 455 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2021, down from 505 in Q2 2021.
- Funds reported $7.39B of Jazz Pharmaceuticals stock for Q3 2021, down 27% quarter-over-quarter.
- 54 funds opened new Jazz Pharmaceuticals positions in Q3 2021 and 100 closed out, a net change of -46 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2021 was Canada Pension Plan Investment Board, an estimated $163M added.
- The largest Jazz Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $138M sold.
Based on aggregated 13F filings for Q3 2021.